GeneDx Stock Plummets 42.85% Despite Record Revenue Growth Ranking 200th in Trading Volume

On April 30, 2025, GeneDx Holdings (WGS) experienced a significant drop of 42.85% in its stock price, with a trading volume of $537 million, ranking 200th in the day's market activity.

GeneDx reported its first-quarter 2025 financial results, highlighting a revenue of $87.1 million, driven by a 62% year-over-year growth in exome and genome test revenue. This substantial increase underscores the company's strong performance in its core testing business.

Despite beating Wall Street's revenue and adjusted earnings expectations for the first quarter of 2025, GeneDx's stock plummeted. This unexpected decline suggests that investors may have been disappointed by other factors not immediately apparent from the financial results.

During the earnings call, GeneDx emphasized its robust revenue performance, particularly in the exome and genome testing sectors. The company's ability to generate significant growth in these areas indicates a strong market demand for its genetic testing services.